Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Crinetics Pharmaceuticals ( (CRNX) ) just unveiled an announcement.
At the annual meeting of Crinetics Pharmaceuticals‘ stockholders held on June 11, 2025, key decisions were made, including the election of three Class I directors for three-year terms, the ratification of BDO USA, P.C. as the independent accounting firm, and the approval of executive compensation. These decisions reflect strong shareholder support and are likely to influence the company’s strategic direction and governance structure.
The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.
Spark’s Take on CRNX Stock
According to Spark, TipRanks’ AI Analyst, CRNX is a Neutral.
Crinetics Pharmaceuticals has a moderate overall score due to financial challenges, including persistent losses and cash flow issues. Positive earnings call sentiment and strategic growth plans provide some optimism, but the technical analysis and valuation highlight ongoing financial risks. The company’s ability to execute on its strategic initiatives, particularly the launch of paltusotine, will be crucial for improving its financial health.
To see Spark’s full report on CRNX stock, click here.
More about Crinetics Pharmaceuticals
Crinetics Pharmaceuticals operates in the pharmaceutical industry, focusing on developing therapies for rare endocrine diseases and endocrine-related tumors.
Average Trading Volume: 956,444
Technical Sentiment Signal: Sell
Current Market Cap: $3.1B
See more insights into CRNX stock on TipRanks’ Stock Analysis page.